All IndicationsInfectious DiseasePhase 3Phase 3Phase 3Phase 3Phase 2Phase 2Phase 2Phase 2
🦠
Covid-19
5
Companies
8
Drug Programs
4
Phase 3
0
Upcoming PDUFAs
Competitors
LLY
Eli Lilly and Company
LY3819253
BNTX
BioNTech SE
BNT162b2 (2025/2026 formulation)
BNTX
BioNTech SE
BNT162b2 (Omi LP.8.1)
MRNA
Moderna, Inc.
mRNA-1283
Fast Track
ENTA
Enanta Pharmaceuticals, Inc.
EDP-235
TRAW
Traws Pharma, Inc.
Ratutrelvir (83-0060) non-randomised
BNTX
BioNTech SE
BNT162b3
BNTX
BioNTech SE
BNT162b2s01
| Company | Drug | Phase | Designations | Timeline | Trial ID |
|---|---|---|---|---|---|
| LLY Eli Lilly and Company | LY3819253 | Phase 3 | — | — | — |
| BNTX BioNTech SE | BNT162b2 (2025/2026 formulation) | Phase 3 | — | — | — |
| BNTX BioNTech SE | BNT162b2 (Omi LP.8.1) | Phase 3 | — | — | — |
| MRNA Moderna, Inc. | mRNA-1283 | Phase 3 | FT | — | — |
| ENTA Enanta Pharmaceuticals, Inc. | EDP-235 | Phase 2 | — | — | — |
| TRAW Traws Pharma, Inc. | Ratutrelvir (83-0060) non-randomised | Phase 2 | — | — | — |
| BNTX BioNTech SE | BNT162b3 | Phase 2 | — | — | — |
| BNTX BioNTech SE | BNT162b2s01 | Phase 2 | — | — | — |
Development Stage Distribution
Phase 3
4
Phase 2
4
PDUFA Timeline
No upcoming PDUFA dates for this indication.
Not Financial Advice
All predictions are probabilistic and based on historical data. Past performance does not guarantee future results. Consult a qualified financial advisor.